USP Ingredient Verification Program for APIs

Significant scientific and technological advancements have been made in the past two decades that have enabled continuous manufacturing (CM) of pharmaceuticals.
These include discovery of new routes for chemical synthesis, development of process monitoring and modeling techniques, and modern equipment to handle and transform materials sequentially in a continuous manufacturing line. Despite these advances, there are only a handful of products that have been approved using CM. Many manufacturers are looking to adopt such advanced manufacturing technologies but face barriers in the form of expert knowledge, economic uncertainty, and regulatory risk.
To address these barriers, it is essential to provide a platform where industry, academia, and regulators can convene to discuss, comment on, and collaborate on the best, most relevant research, develop consensus best practices, and solve collective problems.